|
|
|
| The Effect of Vedilizumab Combined with Mesalazine on Intestinal Flora and Inflammatory Factors in Patients with Moderate to Severe Ulcerative Colitis |
| ZOU Lingting, FAN Lin, MENG Fan |
| First-author's address: The First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China |
|
|
|
|
Abstract Objective: To investigate the effects of Vedilizumab combined with Mesalazine on intestinal flora and inflammatory factors in patients with moderate to severe ulcerative colitis. Method: Clinical data of 72 patients with moderate to severe ulcerative colitis in the First Affiliated Hospital of Gannan Medical University from June 2021 to June 2022 were retrospectively analyzed. According to the treatment methods, they were divided into Mesalazine group (34 cases) and combination group (38 cases). The Mesalazine group was given Mesalazine, and the combination group was given Vedilizumab on the basis of the Mesalazine group. The clinical efficacy, intestinal flora, inflammatory factors and oxidative stress levels were compared between the two groups. Result: The total effective rate of the combination group (92.11%) was higher than that of the Mesalazine group (70.59%), the difference was statistically significant (P<0.05). Before treatment, there were no significant differences in intestinal flora indexes, inflammatory factors and oxidative stress levels between the two groups (P>0.05). After treatment, the lactobacillus and bifidobacterium in both groups were higher than those before treatment, and the lactobacillus and bifidobacterium in the combination group were higher than those in the Mesalazine group, the enterococcus in both groups were decreased than those before treatment, and the enterococcus in the combination group was lower than that in the Mesalazine group, the differences were statistically significant (P<0.05). After treatment, the inflammatory factors of the two groups were decreased, and the levels of TNF-α, IL-8 and hs-CRP in the combination group were lower than those in the Mesalazine group (P<0.05). After treatment, the levels of oxidative stress in both groups were improved, and the SOD in the combination group was higher than that in the Mesalazine group, and the malondialdehyde and LPO were lower than those in the Mesalazine group, the differences were statistically significant (P<0.05). Conclusion: Vedilizumab combined with Mesalazine can effectively treat patients with moderate to severe ulcerative colitis, significantly improve intestinal flora, reduce oxidative stress and inflammatory reaction.
|
|
Received: 03 February 2023
|
|
|
|
|
|
|
